Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Verrica Pharmaceuticals Inc
VRCA | US
6.21
USD0.30
5.08%
VRCA | US
About Verrica Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
6.21
Open
6.05
High
6.45
Low
5.67
Verrica Pharmaceuticals Inc. a clinical-stage dermatology therapeutics company develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315 an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions including basal cell carcinoma; and cantharidin-based product candidate VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co. Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester Pennsylvania.
View LessVRCA | US
Risk
106.6
Sharpe
0.07
Luna's Score
43/100
Recommendation
Sell
Luna says (VRCA | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
101.2%1 month
106.6%3 months
85.4%6 months
114.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
238.54
Debt to equity
-3.48
Debt to assets
0.89
Ent. to EBITDA
-11.70
Ent. to rev.
5.94
PEG
-
Other Fundamentals
EBITDA
-77.52M
MarketCap
264.97M
MarketCap(USD)
264.97M
Div. yield
-
Op. margin
-293.72
Erngs. growth
-
Rev. growth
2.74K
Ret. on equity
-412.98
Short ratio
6.12
Short perc.
19.12
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.34
Range1M
2.29
Range3M
4.00
Volumes: Market Activity
Rel. volume
1.41
Price X volume
954.43K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.70 | - | Cheaper |
| Ent. to Revenue | 5.94 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 238.54 | 15.55 | Expensive |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 85.38 | - | Par |
| Debt to Equity | -3.48 | -1.23 | Cheaper |
| Debt to Assets | 0.89 | 0.25 | Expensive |
| Market Cap | 264.97M | - | Emerging |
